In:
Blood Advances, American Society of Hematology, Vol. 1, No. 17 ( 2017-07-25), p. 1324-1334
Kurzfassung:
CHL broadly expresses the PD-1/PD-L1 pathway, but EBV+ CHL displays a Th1 profile, whereas EBV− tumors have a pathogenic Th17 profile. These findings support further studies to define the role of the IL-23/IL-17 axis in CHL response/resistance to anti-PD-1 therapy.
Materialart:
Online-Ressource
ISSN:
2473-9529
,
2473-9537
DOI:
10.1182/bloodadvances.2017007260
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2017
ZDB Id:
2876449-3